<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04263649</url>
  </required_header>
  <id_info>
    <org_study_id>MDS-19PICCEU01</org_study_id>
    <nct_id>NCT04263649</nct_id>
  </id_info>
  <brief_title>Prospective Observational Study of the Power PICC Family of Devices and Accessories</brief_title>
  <official_title>Prospective Observational Study of the Power PICC Family of Devices and Accessories</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Becton, Dickinson and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FGK Clinical Research GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Becton, Dickinson and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post-market, observational study to collect prospective data related to the safety and
      performance of the Power PICC family of devices and its accessories in a real-world setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single-arm, post-market, observational, prospective study to asses the safety and performance
      of the Power PICC Power PICC family of devices and its accessories in a real-world setting.
      The study will only enroll patients that need a Power PICC catheter as part of their medical
      care. Patients will be followed from insertion through removal, or up to 180 days (whichever
      comes first). Data collected will be gathered from the patient's medical chart.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 18, 2020</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of venous thrombosis</measure>
    <time_frame>from insertion though removal or 180 days, whichever comes first</time_frame>
    <description>Incidence of venous thrombosis defined as any new occurrence of symptomatic venous thrombosis defined by thrombus presence by ultrasonography or other imaging</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent PICC remain in place through therapy</measure>
    <time_frame>from insertion though removal or 180 days, whichever comes first</time_frame>
    <description>Percent of PICCs that remain in place through the required therapy time period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of phlebitis</measure>
    <time_frame>from insertion though removal or 180 days, whichever comes first</time_frame>
    <description>Incidence of phlebitis where phlebitis is defined inflammation of the cannulated vessel identified by redness, swelling, warmth, tenderness, and/or cord formation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of extravasation</measure>
    <time_frame>from insertion though removal or 180 days, whichever comes first</time_frame>
    <description>Incidence of extravasation where extravasation is defined as accidental infiltration of a vesicant or chemotherapeutic drug into the tissue around the catheter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of local infection</measure>
    <time_frame>from insertion though removal or 180 days, whichever comes first</time_frame>
    <description>Incidence of local infection where local infection is defined as presence of pus at the exit site and/or culture confirmed site infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Catheter-related bloodstream infection</measure>
    <time_frame>from insertion though removal or 180 days, whichever comes first</time_frame>
    <description>Incidence of Catheter-related bloodstream infection where Catheter-related bloodstream infection is defined as positive blood culture(s) with a microorganism not related to another source (e.g., UTI) OR positive blood culture(s) with microorganism matching catheter tip culture OR blood cultures from peripheral venous puncture and PICC positive with the same microorganism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Accidental dislodgement</measure>
    <time_frame>from insertion though removal or 180 days, whichever comes first</time_frame>
    <description>Incidence of Accidental dislodgement where Accidental dislodgement is defined as catheter accidentally dislodged the extent to which it requires replacement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of vessel laceration</measure>
    <time_frame>during the insertion procedure</time_frame>
    <description>Incidence of vessel laceration where vessel laceration is defined as a tear in the tissue of the vessel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of vessel perforation</measure>
    <time_frame>during the insertion procedure</time_frame>
    <description>Incidence of vessel perforation where vessel perforation is defined as a hole formed in the vessel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of patent catheters</measure>
    <time_frame>from insertion though removal or 180 days, whichever comes first</time_frame>
    <description>Percent of patent catheters defined as the number of functional catheters through therapy/total number of catheters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of placement success in single insertion attempt</measure>
    <time_frame>during the insertion procedure</time_frame>
    <description>Percent of placement success in single insertion attempt defined as placement success defined as single insertion attempt, proper tip location, and patent catheter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ease of insertion</measure>
    <time_frame>during the insertion procedure</time_frame>
    <description>Ease of insertion determined by composite score of guidewire/stylet performance based on post-insertion survey (5 point Likert scale)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Peripherally Inserted Central Catheter</condition>
  <arm_group>
    <arm_group_label>All subjects</arm_group_label>
    <description>patients who require a PICC</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Peripherally Inserted Central Catheter</intervention_name>
    <description>insertion of a Peripherally Inserted Central Catheter (PICC)</description>
    <arm_group_label>All subjects</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Any patients who require a PICC device in a primary care facility.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any patient, regardless of age or gender, for which the investigator has decided that
             one of the PowerPICC study devices for either short-or long-term venous access should
             be inserted as standard of care

          -  Expected to be available for observation through the duration of PICC therapy
             (including outpatient therapy, if applicable)

          -  Provision of signed and dated informed consent form (Note: Consent of guardian or
             parent may be required for patients under the age of 18 years; participant assent may
             be required as well.)

        Exclusion Criteria:

          -  Presence of any device-related infection, bacteremia, or septicemia is known or
             suspected

          -  Body size is insufficient to accommodate the size of implanted device

          -  Known or suspected to be allergic to materials contained in the device

          -  History of irradiation of prospective insertion site

          -  Previous episode(s) of venous thrombosis or vascular surgical procedures at the
             prospective placement site

          -  Local tissue factors which would prevent proper device stabilization and/or access
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klaus Hoerauf, MD</last_name>
    <role>Study Director</role>
    <affiliation>Becton, Dickinson and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Winfried Huesmann</last_name>
    <phone>004915154403197</phone>
    <email>winfried.huesmann@bd.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sandra van Guldener</last_name>
    <phone>0031646900840</phone>
    <email>sandra.vanguldener@bd.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sygehus Soenderjylland, Sønderborg</name>
      <address>
        <city>Sønderborg</city>
        <zip>6400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jana Peric, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HAGA Ziekenhuis</name>
      <address>
        <city>Den Haag</city>
        <zip>2545</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans van Overhagen, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 7, 2020</study_first_submitted>
  <study_first_submitted_qc>February 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2020</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

